SCHEMBL6697663

SCHEMBL6697663

CN1CCN(C(=O)c2ccc(N3CCN(C(c4ccccc4)c4ccccc4)CC3)c(NC(=O)Nc3ccccc3)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KMT2A Q03164 4/20 0.49
MAOB P27338 1/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
EPHX2 P34913 3/20 0.47
NPY2R P49146 1/20 0.47
TSHR P16473 1/20 0.47
NR2E1 Q9Y466 1/20 0.45
GAA P10253 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701730 0.89 KMT2A (0.48) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6697438 0.86 HTT (0.55) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6698658 0.85 KMT2A (0.50) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6686127 0.84 MAPT (0.51) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL29968131 0.84 MAPT (0.51) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL6701834 0.84 TSHR (0.47) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6698300 0.84 HTT (0.52) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6701774 0.83 KDM4E (0.47) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL6701311 0.83 KMT2A (0.45) ALDH1A1KMT2AMAOBMAPTKDM4E
SCHEMBL6702347 0.83 OPRD1 (0.44) ALDH1A1KMT2AMAOBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-25 US claimed
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LTD (AU) 2025-01-16 US disclosed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed
WO-2022192252-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2022-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY ARRB1, ADRB2, ADRB1 ALDH1A1 1917/4885KMT2A 3828/4885MAOB 176/4885
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 ALDH1A1 1583/4885KMT2A 4455/4885MAOB 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.